跳至主要内容
临床试验/IRCT20240627062267N1
IRCT20240627062267N1招募中3 期

Comparative analysis of the efficacy of Irinotecan-loaded drug-eluting beads (DEBIRI) in combination with systemic chemotherapy versus chemotherapy alone in unresectable colorectal cancer liver metastases: a randomized clinical trial

Tehran University of Medical Sciences0 个研究点目标入组 116 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
116

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Patients with histologically proven, unresectable or borderline resectable liver metastases from colorectal origin, who are 18 years or older and
  • Patients who are chemotherapy-naïve for their metastatic disease
  • Metastases burden must be exclusively or predominantly limited to the liver.
  • Adequate hematologic, hepatic, and renal function ( ANC = 1.5 × 10^9/L•PLT = 75 × 10^9/L•INR = 1.3•Total bilirubin = 2.0 mg/dL•AST and ALT = ×5 the upper limit of normal (ULN)•Albumin = 2.5 g/dL•Creatinine = 2.0 mg/dL)
  • Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less

排除标准

  • Patients who are candidates for curative surgery without the need for neoadjuvant therapy
  • Liver involvement of = 70%
  • Presence of brain metastases
  • Peritoneal carcinomatosis
  • Presence or History of an allergic reaction to any of the study drugs
  • Chronic viral hepatitis B or C
  • Pregnancy (based on elevated serum or urine B-HCG level)
  • Breastfeeding
  • Patient’s refusal to participate in the study

研究者

相似试验